Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy

HIV Medicine

Volumn 14, Issue 6, 2013, Pages 370-378

  Grint, D ^a   Peters, L ^b   Reekie, J ^a   Soriano, V ^c   Kirk, O ^b,d   Knysz, B ^e   Suetnov, O ^f   Lazzarin, A ^g   Ledergerber, B ^h   Rockstroh, J K ⁱ   Mocroft, A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d Rigshospitalet   (Denmark)

^e WROCLAW MEDICAL UNIVERSITY   (Poland)

^f Regional AIDS Centre   (Belarus)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ UNIVERSITY OF BONN   (Germany)

Author keywords

Combination antiretroviral therapy; Hepatitis C virus; Hepatitis C virus RNA; HIV; Viraemia

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; EUROPE; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; PROSPECTIVE STUDIES; RNA, VIRAL; VIRAL LOAD;

EID: 84878944412     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12033     Document Type: Article

References (32)

1. Soriano V, Puoti M, Sulkowski M etal. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. Aids 2007; 21: 73-89.
2. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-infection. Antiviral Res 2010; 85: 3-15.
3. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural-history of hepatitis-C virus-infection in multitransfused hemophiliacs - effect of coinfection with human-immunodeficiency-virus. J Acquir Immune Defic Syndr Hum Retrovirol 1993; 6: 2-10.
4. Fishbein DA, Lo YT, Netski D, Thomas DL, Klein RS. Predictors of hepatitis C virus RNA levels in a prospective cohort study of drug users. Jaids J Acquir Immune Defic Syndr 2006; 41: 71-76.
5. Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas CM. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999; 179: 254-258.
6. Rockstroh JK, Mocroft A, Soriano V etal. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192: 92-1002.
7. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. Aids 2004; 18: 39-45.
8. Mocroft A, Soriano V, Rockstroh J etal. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? Aids 2005; 19: 117-125.
9. Weber R. Liver-related deaths in persons infected with the human immunodeficiency virus - The D : A : D study. Arch Intern Med 2006; 166: 632-641.
10. Weis N, Lindhardt BO, Kronborg G etal. Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a Nationwide Cohort Study. Clin Infect Dis 2006; 42: 481-487.
11. Soriano V, Garcia-Samaniego J, Rodriguez-Rosado R, Gonzalez J, Pedreira J. Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. J Hepatol 1999; 31: 119-123.
12. Torriani FJ, Rodriguez-Torres M, Rockstroh JK etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 38-50.
13. McCarthy JJ, Li JH, Thompson A etal. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 307-314.
14. Herrero-Martinez E, Sabin CA, Evans JG, Griffioen A, Lee CA, Emery VC. The prognostic value of a single hepatitis C virus RNA load measurement taken early after human immunodeficiency virus seroconversion. J Infect Dis 2002; 186: 70-76.
15. Thomas DL, Astemborski J, Vlahov D etal. Determinants of the quantity of hepatitis C virus RNA. J Infect Dis 2000; 181: 44-51.
16. Yeo AET, Ghany M, Conry-Cantilena C etal. Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. J Viral Hepat 2001; 8: 56-63.
17. Eyster ME, Fried MW, Dibisceglie AM, Goedert JJ. Increasing hepatitis-C virus-rna levels in hemophiliacs - relationship to human-immunodeficiency-virus infection and liver-disease. Blood 1994; 84: 020-023.
18. Mocroft A, Ledergerber B, Katlama C etal. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 2-9.
19. Soriano V, Mocroft A, Rockstroh J etal. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008; 198: 337-344.
20. Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C Virus transmission? Hepatology 2010; 52: 497-505.
21. Hollingsworth RC, Sillekens P, vanDeursen P, Neal KR, Irving WL. Serum HCV RNA levels assessed by quantitative NASBA(R): stability of viral load over time, and lack of correlation with liver disease. J Hepatol 1996; 25: 01-06.
22. Chen Y. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-a and ribavirin. Aliment Pharmacol Ther 2012; 36: 1-103.
23. Peters L, Grint D, Lundgren JD etal. Chronic Hepatitis C (HCV) Infection and Chronic Kidney Disease (CKD) in HIV-infrected Patients in the EuroSIDA Study. 13th European Aids Conference (EACS). Belgrade, Serbia, October 2011 [Abstract PS7/3].
24. Mocroft A, Neuhaus J, Peters L etal. for the INSIGHT SMART and ESPRIT Study Groups. Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS ONE 2012; 7: e40245.
25. Thompson AJ, Muir AJ, Sulkowski MS etal. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 20-U178.
26. Bower WA, Culver DH, Castor D etal. Changes in hepatitis C virus (HCV) viral load and interferon-alpha levels in HIV/HCV-coinfected patients treated with highly active antiretroviral therapy. Jaids J Acquir Immune Defic Syndr 2006; 42: 93-97.
27. Rutschmann OT, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin LH. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998; 177: 83-85.
28. Chung RT, Evans SR, Yang YJ etal. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. Aids 2002; 16: 915-923.
29. Rohrbach J, Robinson N, Harcourt G etal. Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut 2010; 59: 252-258.
30. Cooper C. Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection. Clin Infect Dis 2002; 35: 73-79.
31. Konopnicki D, Mocroft A, de Wit S etal. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. Aids 2005; 19: 93-601.
32. Martin-Carbonero L, Barreiro P, Jimenez-Galan G, Garcia-Berriguete R, Nunez M. Clearance of hepatitis C virus in HIV-infected patients with multiple chronic viral hepatitis. J Viral Hepat 2007; 14: 92-95.